Welcome to our dedicated page for ICON news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON stock.
ICON plc reports developments for a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology companies. Its news commonly covers operating and financial results, clinical trial management activity, net business wins, revenue guidance, and service areas such as patient recruitment, data analytics, laboratory services and regulatory consulting.
Company updates also address partnerships that connect clinical trial technology with research-site systems, expansion of the Accellacare Site Network in therapeutic areas including oncology, and governance or accounting-control matters tied to revenue recognition and financial reporting.
ICON plc (NASDAQ: ICLR) announced that CFO Brendan Brennan will present at two upcoming virtual healthcare conferences. The first is the 29th Annual Credit Suisse Virtual Healthcare Conference on November 9, 2020, starting at 08:45 ET, followed by the Evercore ISI HealthCONx Conference on December 2, 2020, at 11:20 ET. Links to live webcasts and any changes will be updated in the Investor section of ICON's website. As of September 30, 2020, ICON employed approximately 15,250 staff across 94 locations globally.
ICON plc (NASDAQ: ICLR) reported robust financial results for Q3 2020, achieving a record $990 million in net business wins, with a book-to-bill ratio of 1.41. Despite a 1.2% year-on-year decline in revenue to $701.7 million, the company raised its 2020 revenue guidance to $2,750 million - $2,810 million. Operational income for the quarter was $108.4 million, and the net income was $91.6 million. The company reported net cash of $359.8 million, up from $244.0 million in Q2 2020. ICON is well-positioned to leverage COVID-19 opportunities, managing over 100 trials related to the pandemic.
Summary not available.